Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jan 3, 2026

A BW Reporter System for Studying Receptor-Ligand Interactions
06:05

A BW Reporter System for Studying Receptor-Ligand Interactions

Published on: January 7, 2019

8.1K

Patterns of B Cell Repletion Following Rituximab Therapy in a Pediatric Rheumatology Cohort.

Chace Mitchell1, Courtney B Crayne1, Randy Q Cron1

  • 1University of Alabama at Birmingham.

ACR Open Rheumatology
|November 29, 2019
PubMed
Summary

Rituximab (RTX) therapy for pediatric rheumatic diseases shows variable B cell repletion. B cell normalization at 12 months is independent of disease type or RTX rounds, but early depletion impacts long-term recovery.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Type I Interferon and Still Disease.

Arthritis & rheumatology (Hoboken, N.J.)·2026
Same author

Hemophagocytic Lymphohistiocytosis Gene Variants in Severe COVID-19 Cytokine Storm Syndrome.

Viruses·2025
Same author

Genetic challenges in the hole puncher.

Blood·2025
Same author

Hospitalized with fever: worthy of serum ferritin.

Rheumatology (Oxford, England)·2025
Same author

Surgical outcomes of the reinforced Ross procedure in the pediatric population.

JTCVS open·2025
Same author

Diagnostic guidelines for familial hemophagocytic lymphohistiocytosis revisited.

Blood·2024

Area of Science:

  • Pediatric Rheumatology
  • Immunology
  • Pharmacology

Background:

  • Rituximab (RTX) is an immunosuppressive therapy used for various pediatric rheumatic diseases.
  • Understanding B cell dynamics post-RTX is crucial for treatment monitoring and predicting outcomes.

Purpose of the Study:

  • To investigate factors influencing B cell repletion after RTX therapy in children.
  • To examine the association between demographic/disease characteristics, RTX rounds, and concurrent immunosuppression with B cell recovery.

Main Methods:

  • Retrospective chart review of 112 pediatric patients treated with RTX.
  • Analysis of CD19 levels at 6 and 12 months post-RTX.
  • Comparison of demographic, clinical, and laboratory data.

More Related Videos

Flow Cytometric Characterization of Murine B Cell Development
08:25

Flow Cytometric Characterization of Murine B Cell Development

Published on: January 22, 2021

18.2K
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

502

Related Experiment Videos

Last Updated: Jan 3, 2026

A BW Reporter System for Studying Receptor-Ligand Interactions
06:05

A BW Reporter System for Studying Receptor-Ligand Interactions

Published on: January 7, 2019

8.1K
Flow Cytometric Characterization of Murine B Cell Development
08:25

Flow Cytometric Characterization of Murine B Cell Development

Published on: January 22, 2021

18.2K
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

502

Main Results:

  • 48% of patients had persistent B cell depletion at 6 months; 89% achieved repletion (≥10 cells/μL) by 12 months.
  • 46% of patients remained below normal B cell levels (≥170 cells/μL) at 12 months.
  • No significant association found between RTX rounds or disease type and persistent depletion; 6-month depletion predicted 12-month depletion.

Conclusions:

  • Rituximab therapy is generally well-tolerated in pediatric rheumatic diseases.
  • B cell repletion following RTX is variable and not dependent on the number of infusions or underlying disease.
  • Early B cell depletion at 6 months is a strong predictor of persistent depletion at 12 months.